Atara Biotherapeutics (NASDAQ:ATRA) Given a $14.00 Price Target by Citigroup Analysts

Citigroup set a $14.00 price target on Atara Biotherapeutics (NASDAQ:ATRA) in a report published on Monday, TipRanks reports. The firm currently has a hold rating on the biotechnology company’s stock.

Several other analysts have also commented on the company. Mizuho reissued a buy rating and issued a $62.00 price objective on shares of Atara Biotherapeutics in a report on Thursday, May 9th. William Blair reissued a buy rating on shares of Atara Biotherapeutics in a report on Thursday, May 16th. BidaskClub raised Atara Biotherapeutics from a strong sell rating to a sell rating in a report on Tuesday. Stifel Nicolaus initiated coverage on Atara Biotherapeutics in a report on Wednesday, May 22nd. They issued a buy rating and a $41.00 price objective on the stock. Finally, Wedbush reissued an outperform rating on shares of Atara Biotherapeutics in a report on Wednesday, May 29th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $39.67.

ATRA stock traded down $0.06 during trading on Monday, hitting $14.05. 836,523 shares of the company traded hands, compared to its average volume of 660,151. The stock’s 50-day moving average is $16.23. The company has a current ratio of 9.96, a quick ratio of 9.96 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $715.52 million, a P/E ratio of -2.66 and a beta of 2.08. Atara Biotherapeutics has a 1 year low of $11.89 and a 1 year high of $43.95.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($1.45) by ($0.15). Research analysts predict that Atara Biotherapeutics will post -5.54 earnings per share for the current year.

In related news, Director Eric Dobmeier acquired 2,000 shares of the stock in a transaction on Thursday, June 27th. The shares were bought at an average price of $19.50 per share, with a total value of $39,000.00. Following the completion of the purchase, the director now owns 16,000 shares of the company’s stock, valued at approximately $312,000. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Isaac E. Ciechanover sold 5,850 shares of the business’s stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $23.09, for a total value of $135,076.50. Following the transaction, the chief executive officer now directly owns 332,243 shares in the company, valued at approximately $7,671,490.87. The disclosure for this sale can be found here. Insiders own 7.00% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Manchester Capital Management LLC acquired a new position in Atara Biotherapeutics during the first quarter worth $56,000. Aperio Group LLC acquired a new position in Atara Biotherapeutics during the second quarter worth $63,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its stake in Atara Biotherapeutics by 12.7% during the first quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 4,554 shares of the biotechnology company’s stock worth $181,000 after buying an additional 512 shares during the last quarter. Highland Private Wealth Management acquired a new position in Atara Biotherapeutics during the first quarter worth $219,000. Finally, Amalgamated Bank acquired a new position in Atara Biotherapeutics during the fourth quarter worth $212,000.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Recommended Story: What is a portfolio manager?

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.